Medline (NASDAQ:MDLN) Research Coverage Started at Wolfe Research

Wolfe Research assumed coverage on shares of Medline (NASDAQ:MDLN) in a research report released on Monday morning, MarketBeat reports. The brokerage issued an outperform rating and a $47.00 price objective on the stock.

Several other equities research analysts have also recently weighed in on MDLN. Wall Street Zen raised Medline to a “hold” rating in a research note on Saturday, January 10th. Leerink Partners initiated coverage on shares of Medline in a report on Monday. They set an “outperform” rating and a $48.00 target price on the stock. Robert W. Baird initiated coverage on shares of Medline in a research note on Monday. They issued an “outperform” rating and a $48.00 price target for the company. Piper Sandler assumed coverage on shares of Medline in a research report on Monday. They set an “overweight” rating and a $50.00 price target for the company. Finally, Evercore ISI initiated coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $50.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.70.

Medline Stock Performance

Shares of NASDAQ:MDLN opened at $43.41 on Monday. Medline has a 52-week low of $34.89 and a 52-week high of $45.50.

Insider Activity

In other news, Director Andrew J. Mills acquired 2,586,206 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the transaction, the director owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider owned 4,806,160 shares of the company’s stock, valued at approximately $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.